Goldman Sachs Group Inc. Takes $546,000 Position in LENSAR, Inc. $LNSR

Key Points

• Goldman Sachs Group Inc. has purchased a new position in LENSAR, Inc., acquiring 38,680 shares valued at approximately $546,000, representing about 0.33% of the company's stock.
• Several other institutional investors, including Gabelli Funds LLC and Nuveen LLC, also initiated new stakes in LENSAR during the first quarter, contributing to a total institutional ownership of 40.15%.
• LENSAR reported a loss of ($0.15) EPS in its latest earnings, falling short of the expected ($0.08) EPS, with revenue of $11.36 million compared to the anticipated $16.55 million.

Goldman Sachs Group Inc. purchased a new position in LENSAR, Inc. (NASDAQ:LNSR - Free Report) in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 38,680 shares of the company's stock, valued at approximately $546,000. Goldman Sachs Group Inc. owned approximately 0.33% of LENSAR as of its most recent SEC filing.

Several other large investors have also added to or reduced their stakes in LNSR. Gabelli Funds LLC purchased a new stake in shares of LENSAR in the first quarter worth $191,000. PenderFund Capital Management Ltd. bought a new position in LENSAR in the 1st quarter worth $236,000. Nuveen LLC purchased a new stake in LENSAR in the 1st quarter worth $252,000. Acadian Asset Management LLC bought a new stake in LENSAR during the first quarter valued at about $257,000. Finally, Cubist Systematic Strategies LLC bought a new stake in LENSAR during the first quarter valued at about $369,000. Hedge funds and other institutional investors own 40.15% of the company's stock.

LENSAR Stock Down 0.7%

NASDAQ LNSR opened at $12.06 on Friday. The firm has a market cap of $144.00 million, a price-to-earnings ratio of -2.86 and a beta of 0.49. The business has a 50-day moving average price of $12.62 and a 200-day moving average price of $13.29. LENSAR, Inc. has a twelve month low of $4.20 and a twelve month high of $17.31.

LENSAR (NASDAQ:LNSR - Get Free Report) last released its earnings results on Thursday, August 7th. The company reported ($0.15) EPS for the quarter, missing the consensus estimate of ($0.08) by ($0.07). The company had revenue of $11.36 million during the quarter, compared to analysts' expectations of $16.55 million. LENSAR had a negative return on equity of 737.30% and a negative net margin of 84.49%.

LENSAR Profile

LENSAR, Inc, a commercial-stage medical device company, focuses on designing, developing, and marketing a femtosecond laser system for the treatment of cataracts and the management of pre-existing or surgically induced corneal astigmatism. It offers LENSAR Laser System that incorporates a range of proprietary technologies designed to assist the surgeon in obtaining visual outcomes, efficiency, and reproducibility by providing imaging, procedure planning, design, and precision.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.